<div id="readability-page-1"><div><ul> <li>Madrigal Pharmaceuticals recently appointed industry veteran Rita Thakkar as Senior Vice President and Chief Accounting Officer, while continuing to expand commercial access and international availability of its MASH therapy Rezdiffra, including a launch in Germany.</li> <li>The combination of strengthened financial leadership and widening Rezdiffra uptake, supported by broad first-line payer coverage, highlights a focus on scaling disciplined, global growth in MASH treatment.</li> <li>We’ll now examine how Rezdiffra’s broad first-line payer access and growing international footprint may influence Madrigal’s existing investment narrative.</li> </ul><p>AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</p><h2>Madrigal Pharmaceuticals Investment Narrative Recap</h2><p>To own Madrigal, you have to believe Rezdiffra can become a durable, globally adopted MASH therapy while the company manages single‑drug concentration risk and rising competition. The appointment of seasoned accounting leadership and broad first line payer access do not materially change the near term commercial execution catalyst or the key risk that any setback in Rezdiffra’s data or safety profile could hit revenues hard.</p> <p>Against this backdrop, H.C. Wainwright’s recent price target increase, citing strong Rezdiffra uptake and broad 2026 first line payer coverage, looks most relevant, because it directly ties current sentiment to how effectively Madrigal converts early access and international launches into sustained prescription growth during this critical commercialization phase.</p> <p>Yet investors should also be aware that, even with growing payer access, intensifying GLP 1 and MASH competition could still...</p> <p>Read the full narrative on Madrigal Pharmaceuticals (it's free!)</p><p>Madrigal Pharmaceuticals' narrative projects $2.5 billion revenue and $822.9 million earnings by 2028.</p><p>Uncover how Madrigal Pharmaceuticals' forecasts yield a $563.80 fair value, in line with its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7343c1eb-90d9-4931-ae9a-2d15cb611ffd/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7343c1eb-90d9-4931-ae9a-2d15cb611ffd/chart/quote-price"/><figcaption>MDGL 1-Year Stock Price Chart</figcaption></figure> <p>Six fair value estimates from the Simply Wall St Community span roughly US$460 to US$2,878, showing how far apart individual views on Madrigal’s potential can be. When you weigh those opinions against the reliance on a single lead asset and the importance of Rezdiffra’s ongoing clinical and commercial performance, it becomes even more important to compare several perspectives before deciding where you stand.</p><p>Explore 6 other fair value estimates on Madrigal Pharmaceuticals - why the stock might be worth 20% less than the current price!</p><h2>Build Your Own Madrigal Pharmaceuticals Narrative</h2><p>Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free Madrigal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Madrigal Pharmaceuticals' overall financial health at a glance.</li></ul><h2>Looking For Alternative Opportunities?</h2><p>Every day counts. These free picks are already gaining attention. See them before the crowd does:</p><ul><li>We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</li><li>Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.</li><li>Find companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><p>Mobile Infrastructure for Defense and Disaster</p><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p><p>Get the investor briefing before the next round of contracts</p><p><span>Sponsored On Behalf of CiTech</span></p></div></div></div>

MDGL

<p>Madrigal Pharmaceuticals has appointed Rita Thakkar as Senior VP and Chief Accounting Officer, while expanding access to its MASH therapy, Rezdiffra, including a launch in Germany. This move aims to enhance global growth and financial leadership. Despite these developments, the company faces risks from single-drug concentration and competition. H.C. Wainwright increased its price target, citing strong Rezdiffra uptake. Investors should consider various perspectives on Madrigal's potential, as fair value estimates vary widely. The company's narrative projects significant revenue and earnings growth by 2028.</p>

How Investors May Respond To Madrigal Pharmaceuticals (MDGL) Expanding Rezdiffra Access And Strengthening Finance Leadership